UNSPSC 51313303: Tolpropamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TBZ8909KFS, chemically known as n,n-dimethyl-3-phenyl-3-p-tolylpropylamine but generally known as tolpropamine, which bears US NIH Compound Identifier 72141. European Medicines Agency schedules Tolpropamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11176MIG.

UNSPSC 51313303 Tolpropamine is a Commodity code that, based on recent state and local procurement activity, does not reflect the actual scope of work being solicited under it. The three recent opportunities posted against this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which are tolpropamine-specific. The mismatch between the code's nominal pharmaceutical designation and the actual health and human services purchasing activity suggests the code is being used as a catch-all taxonomy for state and local pharmaceutical procurement rather than for tolpropamine purchases in particular. Issuing bodies across these opportunities include county health systems (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work being solicited ranges from community health supply procurement to exploratory market-intelligence gathering on direct contracting models and multi-state generic pharmaceutical frameworks.

Geographic activity clusters around the Midwest and South, with documented opportunities in Minnesota, Texas, and Florida. The most recent representative opportunities include Seminole County's IFB60459723LAS (released June 30, 2026, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products supplied through authorized wholesalers AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson. All three opportunities require electronic submission, compliance with federal manufacturing and supply-chain standards, and adherence to state and local insurance and employment-eligibility verification requirements.